Who are AERAS-402 3 x 10^8 vp's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Hep-V Vax, TT, batch 3 of Ad5-nCoV, rVSV∆G-ZEBOV-GP, Ad26.COV2.S vaccine, batch 1 of Ad5-nCoV.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aeras-402-3-x-10-8-vp.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

AERAS-402 3 x 10^8 vp — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AERAS-402 3 x 10^8 vp (AERAS-402 3 x 10^8 vp) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Viral vector vaccine. Area: Immunology / Infectious Disease.

phase 2 Viral vector vaccine Mycobacterium tuberculosis antigens (Ag85A, TB10.4) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

AERAS-402 3 x 10^8 vp (AERAS-402 3 x 10^8 vp) — Aeras. AERAS-402 is a replication-deficient adenovirus vector vaccine that expresses Mycobacterium tuberculosis antigens to stimulate immune responses against tuberculosis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AERAS-402 3 x 10^8 vp TARGET	AERAS-402 3 x 10^8 vp	Aeras	phase 2	Viral vector vaccine	Mycobacterium tuberculosis antigens (Ag85A, TB10.4)
Hep-V Vax	Hep-V Vax	University of Oxford	marketed	Viral vector vaccine	Hepatitis C virus antigens
TT	TT	CanSino Biologics Inc.	marketed	Viral vector vaccine	SARS-CoV-2 spike protein
batch 3 of Ad5-nCoV	batch 3 of Ad5-nCoV	Jiangsu Province Centers for Disease Control and Prevention	marketed	viral vector vaccine	SARS-CoV-2 spike protein
rVSV∆G-ZEBOV-GP	rVSV∆G-ZEBOV-GP	University of Birmingham	marketed	Live attenuated viral vector vaccine	Zaire ebolavirus glycoprotein (EBOV-GP)
Ad26.COV2.S vaccine	Ad26.COV2.S vaccine	University Medical Center Groningen	marketed	viral vector vaccine	SARS-CoV-2 spike protein
batch 1 of Ad5-nCoV	batch 1 of Ad5-nCoV	Jiangsu Province Centers for Disease Control and Prevention	marketed	viral vector vaccine	SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Viral vector vaccine class)

Janssen Vaccines & Prevention B.V. · 5 drugs in this class
University of Oxford · 3 drugs in this class
Crucell Holland BV · 3 drugs in this class
National Institute of Allergy and Infectious Diseases (NIAID) · 2 drugs in this class
Bharat Biotech International Limited · 2 drugs in this class
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation · 1 drug in this class
London School of Hygiene and Tropical Medicine · 1 drug in this class
Samia Hassan El-Shishtawy · 1 drug in this class
University Medicine Greifswald · 1 drug in this class
Aeras · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AERAS-402 3 x 10^8 vp — Competitive Intelligence Brief. https://druglandscape.com/ci/aeras-402-3-x-10-8-vp. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab